[Molecular-Targeted Agents as a Novel Therapeutic Tool for Brain Metastases].
Journal
No shinkei geka. Neurological surgery
ISSN: 0301-2603
Titre abrégé: No Shinkei Geka
Pays: Japan
ID NLM: 0377015
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
entrez:
16
2
2022
pubmed:
17
2
2022
medline:
19
2
2022
Statut:
ppublish
Résumé
Brain metastases(BM)follow the nature of the primary cancer, and understanding the associated genomic abnormalities is essential in the construction of therapeutic strategies for BM. BM showed an excellent response to EGFR-TKI, but the duration of the effect was limited to approximately one year. Despite the longer survival of patients with
Identifiants
pubmed: 35169087
pii: 1436204532
doi: 10.11477/mf.1436204532
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
jpn
Sous-ensembles de citation
IM